-+ 0.00%
-+ 0.00%
-+ 0.00%

B of A Securities Downgrades Amphastar Pharma to Underperform, Lowers Price Target to $20

Benzinga·06/29/2026 11:54:38
Listen to the news
B of A Securities analyst Jason Gerberry downgrades Amphastar Pharma (NASDAQ:AMPH) from Neutral to Underperform and lowers the price target from $25 to $20.